Fraud, Waste and Abuse
|
|
- Cordelia Moore
- 8 years ago
- Views:
Transcription
1 Fraud, Waste and Abuse CT - Fraud Hotline submitted by Connecticut The Fraud Hotline at the Department of Social Services (DSS) is a proactive approach to handling complaints regarding fraud and abuse from the community. Complaints received by the fraud hotline are sent to the pharmacy unit at DSS to determine if patients should be placed into selected review for further action. If an individual is arrested for illegally obtaining controlled substances by fraud &/or possession of narcotics, hallucinogens, etc., they are upon discovery immediately enrolled into the pharmacy lock-in program. Corrective Managed Care Program submitted by Maryland The Corrective Managed Care (CMC) Program has been instituted by the Maryland Medicaid Pharmacy program to monitor and promote appropriate use of controlled substances. The CMC program is particularly concerned with the prescribing practices and utilization of opioids and benzodiazepines. Through a monthly review the state identifies Maryland Medicaid recipients who appear to be on duplicate drug therapy, visit multiple prescribers writing for similar medications, and/or patronize multiple pharmacies. The CMC program shares this information about potential drug misuse with the respective recipient prescribers and pharmacy providers. Physicians and pharmacies are asked to intervene. If despite the best efforts of the prescriber and pharmacy, there still continues to be overutilization of a substance by a recipient, a recipient can be locked-in to a single pharmacy. Under a Lock-In pharmacy agreement, the recipient will be required to fill the related medications at one predetermined pharmacy. Providers can also recommend candidates to the MMPP for lock-in review by using a referral form that is posted on the MMPP website. The CMC Program utilizes the Corrective Managed Care Advisory Committee, which is part of the DUR Board, to assist with the review of individual recipients and help set policy regarding efforts to reduce the potential misuse of controlled substances. The Committee meets just prior to the regular quarterly DUR Board meeting and includes all members of the DUR Board. For those recipients where contact with prescribers through means of intervention letters has not changed behavior, the CMC Advisory Committee reviews each recipient s drug and diagnosis history profile. The Committee then advises the MMPP on recommended corrective action, which may include lock-in, further provider education or continued follow-up. The ultimate goal of
2 locking in a recipient and of the CMC program is to ensure that recipients have access to education they need while reducing the harm associated with over-utilizing controlled substances. Stimulants and Opioid Controls submitted by Delaware As a Drug Utilization Review (DUR) initiative, DMMA focused on the abuse potential of short acting stimulants in the adult population and the encouragement of doctors to write for the lessabuseable longer-acting stimulants. While different adults respond differently to various medications and a full range of medications needs to be available for appropriate treatment, short-acting stimulants are more often misused, abused, or illegally sold or purchased as a drug of abuse. The risks for abuse of prescription and illicit stimulants are elevated among individuals being treated for attention deficient hyperactivity disorder (ADHD) with increased potential for "diversion" due to the possible euphoriant effect or the improvement of study skills. Prescription agents abused most often are those with pharmacokinetic characteristics that provide a rapid rise of dopamine and serotonin while the longer-acting stimulants often have lower abuse potential and less street value. Prior to any interventions or policy changes, 61% percent of the DMMA adult population taking medication for ADHD was on short acting stimulants. Delaware was also very high in terms of per captita dispensing of amphetamines and stimulants. DMMA, on the recommendation of the DUR Board, began to require adult patients to try and fail a long acting ADHD medication before use of a shorter acting one would be approved. Longer acting medications also have the additional advantages of improved compliance, less peak-trough effects that can be seen with twice or thrice daily dosing of immediate-release ADHD medications on dosing, as well as the reduced potential for drug diversion. The DUR board approved an educational letter on the use of ADHD medications and the need for a trial of a long acting medication. The letters were sent to 292 physicians who prescribe CNS stimulants in Delaware as well as medication profiles for their relevant patients, representing 732 clients. A response form was included in the mailing giving the physicians a chance to give us feedback on the following: what they thought of the clinical aspects of intervention, whether the patient had tried and failed a long acting medication before, and if that was why the patient was currently on a short acting stimulant. Within two months of the intervention letter and policy implementation, the percentage of ADHD clients on a short acting stimulant dropped to a total of 42%. This number will continue to decrease in Delaware and further progress will be reported in future DUR reports. New monthly opioid analgesic quantity limits changes were another initiative of DMMA. This policy coincided with the increased focus on the epidemic of prescription drug abuse in Delaware. It was enacted to improve the medical management of pain patients being treated chronically and to ensure checks are available for the patient before any questions of dependence or abuse are raised. While prior authorizations have been in place for some time for long acting medications along with a total quantity limit of 200 units per month for short and long acting
3 narcotics combined, no prior authorization or pain contract was needed for short-acting narcotics that were under the quantity limit. An increasing number of Delaware chronic pain patients were being treated long term with only high dose, high quantity, short-acting medications. This included getting the highly abuseable and diverted oxycodone 15mg and oxycodone 30mg tablets. Individuals with chronic pain who are being treated with frequent doses of short-acting opioids on a regular basis can develop intermittent withdrawal symptoms between doses of medications which may act to increase pain. These patients who increase opioid doses in order to achieve pain relief may actually be treating opioid withdrawal while longer acting opioids have steady serum levels so mini withdrawals or rebound reactions do not occur as often. Without a prior authorization in place there were no requirements by Medicaid to have controls in place to ensure appropriate treatment, evaluation, and monitoring of these patients. In accordance with the Delaware Board of Medical Licensure discipline guidelines, it was recommended that the current policy be tightened to ensure that these drugs were being used appropriately. New quantity limits were put on highly abuseable short acting medications. Clients now are able to get oxycodone immediate release under the following quantity limitations: oxycodone 15mg maximum of 240 capsules a year, oxycodone 20mg maximum of 120 per year and oxycodone 30 mg maximum of 60 capsules per year, after which a prior auth must be submitting including a pain management contract, pain assessment charts, and documentation of pill counts, and random urine screens. For clients currently getting greater quantities, titration to a longacting opioid medication was required with decreased utilization and frequency of the short acting medication or a rotation to a different short-acting opioid for breakthrough pain that would allow for less frequent dosing and utilization. Exceptions were made for clients being treated for cancer and these patients still have these medications available to them without prior authorization if they have an applicable diagnosis on their medical file or have one submitted on the prescription. Since implementation, there has been a transition to more clients being treated for chronic pain with longer acting medications. On prior authorizations submitted, patients were appropriately converted to long acting medications while the shorter acting medications were subsequently decreased and lowered. There has also been a decreased utilization in short acting narcotics in the 5 months since this policy was initiated. Further decreases are expected as people use up their yearly quantity limit of oxycodone and as awareness increases of the issues surrounding use of high doses and high quantities of narcotics chronically. Since this implementation was very successful and because chronic use of opioid medications has risks and should be monitored with a pain contract and urine screens, DMMA also recommended further restrictions on the criteria on short acting narcotics and further tightening up criteria to ensure abuse won t just shift to other drugs. Currently patients can get 2400 units of lower potency narcotics per year without a prior authorization and without any requirement
4 for a drug urine screen or pain contract. For someone with an addictive tendency, by the time the narcotic quantity used exceeds this threshold; it would be too late to prevent the addiction. As such, it was recommended that all short acting opioid analgesics move to a quantity limit of 120 a month with a yearly quantity limit of 720 triggering the need for a prior authorization to be submitted with a pain contract and documentation of drug screens. After 6 months of 120 tablets a month of a short-acting narcotic, a condition would be considered chronic and should be treated with a long-acting narcotic. The Board approved the recommendation and implementation was planned for July Methadone Edits submitted by New Jersey Another innovative solution implemented by DMAHS and Molina Medicaid Solutions demonstrates the informative relationship that can exist between pharmacy claims processing and medical claims history. New Jersey FamilyCare (NJFC)/Medicaid policy limits payment of claims for Methadone to pharmacies based on this drug s intended medical purpose. Pharmacies are eligible to receive NJFC/Medicaid payments for Methadone when this drug is prescribed for pain management. However, when Methadone is prescribed for the treatment of substance abuse, pharmacies are not eligible to receive payment. For the treatment of substance abuse, Methadone is provided by drug treatment centers and is considered a clinic service. To support the Methadone Edit, clinic claims reflecting payments for Methadone are downloaded to the point-of-sale (POS) system. During POS processing, this information is referenced to determine if a conflicting clinic claim for Methadone on or about the service date of the pharmacy claim is found. If a conflicting claim is found, the pharmacy claim is denied for prior authorization. Development of a Prior Authorization Required Process for Medications without prospective DUR edits submitted by Montana In an effort to combat significant medication overuse/abuse and support patient safety, the pharmacy case management program worked with the department to develop and implement a process for a provider-driven PA required process managed through the point-of-sale system. This process is for medications normally not requiring prior authorization and clients for this program are referred on a case-by-case basis. Implementation of a Drug Not Covered Status in the PDCS/X2 system prevents a client from receiving a selected medication or complete therapeutic class of medications each time a claims is submitted, unless a prior authorization is granted per instructions developed by the provider and the case management pharmacist. Currently approximately 200 patients are enrolled and monitored through this program.
5 This has been an effective means to provide a higher level of management for those patients for who even the lock-in program cannot prevent overuse and misuse of medications. This program has been in effect since FFY 2005.
PRESCRIPTION PAINKILLER OVERDOSES
IMPACT{ POLICY PRESCRIPTION PAINKILLER OVERDOSES National Center for Injury Prevention and Control Division of Unintentional Injury Prevention What s the Issue? In a period of nine months, a tiny Kentucky
More informationArkansas Emergency Department Opioid Prescribing Guidelines
Arkansas Emergency Department Opioid Prescribing Guidelines 1. One medical provider should provide all opioids to treat a patient s chronic pain. 2. The administration of intravenous and intramuscular
More informationMEDICAL ASSISTANCE BULLETIN
ISSUE DATE SUBJECT EFFECTIVE DATE MEDICAL ASSISTANCE BULLETIN NUMBER *See below BY Prior Authorization of Opiate Dependence Treatments Pharmacy Service Leesa M. Allen, Deputy Secretary Office of Medical
More information2015 REPORT Steven W. Schierholt, Esq. Executive Director www.pharmacy.ohio.gov
OHIO AUTOMATED RX REPORTING SYSTEM 2015 REPORT Steven W. Schierholt, Esq. Executive Director www.pharmacy.ohio.gov OHIO AUTOMATED RX REPORTING SYSTEM What is OARRS? To address the growing misuse and diversion
More informationProtecting your employees, physicians and you.
Protecting your employees, physicians and you. Opioid abuse is being talked about every day. Modern Medical has a solution - now with real outcomes. Opioids are the most common drugs prescribed in workers
More informationRhode Island Board of Medical Licensure and Discipline
Rhode Island Board of Medical Licensure and Discipline Considerations Regarding Pharmaceutical Stimulant Prescribing for Attention Deficit Disorders (ADD)/Attention Deficit Hyperactivity Disorder (ADHD)
More informationConsiderations when Using Controlled Substances to Treat Chronic Pain
Considerations when Using Controlled Substances to Treat Chronic Pain By Mary-Beth F. Plum, Pharm.D. Impact of Chronic Pain Acute pain is the body s response to environmental dangers, and it helps protect
More informationMEDICAL ASSISTANCE BULLETIN
ISSUE DATE September 4, 2015 SUBJECT EFFECTIVE DATE September 9, 2015 MEDICAL ASSISTANCE BULLETIN NUMBER *See below BY Prior Authorization of Opiate Dependence Treatments, Oral Buprenorphine Agents - Pharmacy
More informationKansas Medical Assistance Programs Retrospective Drug Utilization Review Provider Education and Intervention Program
Program Outcomes Evaluating, Measuring, and Identifying Patient Care Benefits and Cost Reduction Kansas Medical Assistance Programs Retrospective Drug Utilization Review Provider Education and Intervention
More informationKENTUCKY ADMINISTRATIVE REGULATIONS TITLE 201. GENERAL GOVERNMENT CABINET CHAPTER 9. BOARD OF MEDICAL LICENSURE
KENTUCKY ADMINISTRATIVE REGULATIONS TITLE 201. GENERAL GOVERNMENT CABINET CHAPTER 9. BOARD OF MEDICAL LICENSURE 201 KAR 9:260. Professional standards for prescribing and dispensing controlled substances.
More information02 DEPARTMENT OF PROFESSIONAL AND FINANCIAL REGULATION
Effective June 13, 2010 02-313, 02-373, 02-380, 02-383, 02-396 Chapter 21 page 1 02 DEPARTMENT OF PROFESSIONAL AND FINANCIAL REGULATION 313 BOARD OF DENTAL EXAMINERS 373 BOARD OF LICENSURE IN MEDICINE
More informationMassachusetts Substance Abuse Policy and Practices. Senator Jennifer L. Flanagan Massachusetts Worcester and Middlesex District
Massachusetts Substance Abuse Policy and Practices Senator Jennifer L. Flanagan Massachusetts Worcester and Middlesex District November 2014 Substance Abuse and Addiction National and State opioid abuse
More informationAfter seeing a patient on a Diversion Alert installment..
After seeing a patient on a Diversion Alert installment.. Recommendations from Dr. James Berry of Mercy Recovery Center OVERVIEW OF DIVERSION Manufacture Distribution Pharmacy Patient End -user OPPORTUNITIES
More informationOpioids and the Injured Worker Tools for Successful Outcomes
Opioids and the Injured Worker Tools for Successful Outcomes Tim Pokorney, RPh Director, Clinical Express Scripts Workers' Compensation Division Goals and Objectives Alarming statistics for narcotic utilization,
More informationNarcotic drugs used for pain treatment Version 4.3
Narcotic drugs used for pain treatment Version 4.3 Strategy to restrict the pack sizes or the type of packaging available in public pharmacies. 1. Introduction The document describing the strategy of the
More informationOpioid Treatment Guidelines. Denis G. Patterson, DO University of Nevada, Reno 7/15/2015
Opioid Treatment Guidelines Denis G. Patterson, DO University of Nevada, Reno 7/15/2015 Opioid Treatment Guidelines Opioid Treatment Guidelines Chronic opioid therapy to treat chronic non-cancer pain (CNCP)
More informationWhat Every Practitioner Needs to Know About Controlled Substance Prescribing
What Every Practitioner Needs to Know About Controlled Substance Prescribing New York State Department of Health Use of Controlled Substances Controlled substances can be effective in the treatment of
More informationHAWAII BOARD OF MEDICAL EXAMINERS PAIN MANAGEMENT GUIDELINES
Pursuant to section 453-1.5, Hawaii Revised Statutes, the Board of Medical Examiners ("Board") has established guidelines for physicians with respect to the care and treatment of patients with severe acute
More informationGuidelines for Cancer Pain Management in Substance Misusers Dr Jane Neerkin, Dr Chi-Chi Cheung and Dr Caroline Stirling
Guidelines for Cancer Pain Management in Substance Misusers Dr Jane Neerkin, Dr Chi-Chi Cheung and Dr Caroline Stirling Patients with a substance misuse history are at increased risk of receiving inadequate
More informationAbstral Prescriber and Pharmacist Guide
Abstral Prescriber and Pharmacist Guide fentanyl citrate sublingual tablets Introduction The Abstral Prescriber and Pharmacist Guide is designed to support healthcare professionals in the diagnosis of
More informationPolicy for the issue of permits to prescribe Schedule 8 poisons
Policy for the issue of permits to prescribe Schedule 8 poisons May 2011 Introduction The Victorian Drugs, Poisons and Controlled Substances (DPCS) legislation sets out certain circumstances when a medical
More informationPrescription Drug Monitoring Program Center of Excellence at Brandeis
Prescription Drug Monitoring Program Center of Excellence at Brandeis Notes from the Field NF 4.1 Using PDMPs to Improve Medical Care: Washington State s Data Sharing Initiative with Medicaid and Workers
More informationOpioid Prescribing for Chronic Pain: Guidelines for Marin County Clinicians
Opioid Prescribing for Chronic Pain: Guidelines for Marin County Clinicians Although prescription pain medications are intended to improve the lives of people with pain, their increased use and misuse
More informationNon medical use of prescription medicines existing WHO advice
Non medical use of prescription medicines existing WHO advice Nicolas Clark Management of Substance Abuse Team WHO, Geneva Vienna, June 2010 clarkn@who.int Medical and Pharmaceutical role Recommendations
More informationPrior Authorization of buprenophine/naloxone (Suboxone ) or buprenorphine (Subutex )
June 2010 April 2009 Prior Authorization of buprenophine/naloxone (Suboxone ) or buprenorphine (Subutex ) Effective August 1, West Virginia Medicaid will require prior authorization for all Suboxone and
More informationOpioid Agreement for Center for Pain Management S.C.
Opioid Agreement for Center for Pain Management S.C. Patient Name: DOB: I am the patient named above. I have agreed to use pain medication as part of my treatment for chronic pain. I understand that these
More informationDrug overdose death rates by state per 100,000 people (2008) SOURCE: National Vital Statistics System, 2008
PRESCRITPION DRUG ABUSE: AN EPIDEMIC What is Addiction? By: Lon R. Hays, M.D., M.B.A. Professor and Chairman Department of Psychiatry University of Kentucky Healthcare Addiction is a primary, chronic disease
More informationHow To Get A Prescription In Rhode Island
Controlled Substance Prescribing Laws, The Prescription Monitoring Program, and Preventing Drug Diversion Michael Halse, PharmD PGY1 Resident Pharmacist South County Hospital and Healthcare System Disclosures
More informationSUBOXONE /VIVITROL WEBINAR. Educational Training tool concerning the Non-Methadone Medication Assisted Treatment Policy that is Effective on 1/1/12
SUBOXONE /VIVITROL WEBINAR Educational Training tool concerning the Non-Methadone Medication Assisted Treatment Policy that is Effective on 1/1/12 WEBINAR INTRODUCTIONS Cynthia Parsons- Program Manager
More informationOur Mission. How does Colorado Medicaid Work? Objectives
How does Colorado Medicaid Work? Understanding the Delivery of Pharmaceutical Care Cathy Traugott, JD, RPh Client and Clinical Care Office Pharmacy Unit Manager Department of Health Care Policy and Financing
More informationBuprenorphine/Naloxone Maintenance Treatment for Opioid Dependence
Buprenorphine/Naloxone Maintenance Treatment for Opioid Dependence Information for Family Members Family members of patients who have been prescribed buprenorphine/naloxone for treatment of opioid addiction
More informationPrescribing Standards for Nurse Practitioners (NPs)
Prescribing Standards for Nurse Practitioners (NPs) July 2014 Approved by the College and Association of Registered Nurses of Alberta Provincial Council, (July 2014) Permission to reproduce this document
More informationManaged Care Reforms. Ohio Healthcare Policy and Political Update. Physician Ranking Programs SB 121 - Physician Ranking Programs
Ohio Healthcare Policy and Political Update Jeffrey S. Smith, JD, Director, Government Relations Managed Care Reforms Administrative Simplification SB 136 Health Insurance Modernization Act Prohibit unilateral
More informationSample Patient Agreement Forms
Sample Patient Agreement Forms Introduction This resource includes two sample patient agreement forms that can be used with patients who are beginning long-term treatment with opioid analgesics or other
More informationMEDICAID DRUG SPENDING ON ANTI- ADDICTION MEDICATION AND OPIOID ADDICTION REFRESHER
MEDICAID DRUG SPENDING ON ANTI- ADDICTION MEDICATION AND OPIOID ADDICTION REFRESHER TWO PRIMARY ACCESS POINTS Pharmacy Benefit Dispensed by a Pharmacy Billed via the PBM Process (NCPCP) Oversight by Drug
More informationManaging Chronic Pain in Adults with Substance Use Disorders
Question from chapter 1 Managing Chronic Pain in Adults with Substance Use Disorders 1) What is the percent of chronic pain patients who may have addictive disorders? a) 12% b) 22% c) 32% d) 42% 2) Which
More informationMANAGEMENT OF CHRONIC NON MALIGNANT PAIN
MANAGEMENT OF CHRONIC NON MALIGNANT PAIN Introduction The Manitoba Prescribing Practices Program (MPPP) recognizes the important role served by physicians in relieving pain and suffering and acknowledges
More informationSupport to Primary Care from Derbyshire Substance Misuse Service for prescribed / OTC drug dependence
Support to Primary Care from Derbyshire Substance Misuse Service for prescribed / OTC drug dependence SUMMARY 1) Derbyshire Substance misuse service provides Psycho-social treatment interventions for ALL
More informationPrescription Medication Abuse: Skills for Prevention and Intervention
Prescription Medication Abuse: Skills for Prevention and Intervention icare Partnership www.icarenc.org James Finch, MD North Carolina Society of Addiction Medicine NC Governor s Institute on Alcohol and
More informationAppendices to Interim Report on the Baltimore Buprenorphine Initiative. Managed Care Organization Information Pages
Appendices to Interim Report on the Baltimore Buprenorphine Initiative Appendix A Managed Care Organization Information Pages Appendix B Buprenorphine Online Physician Training Information Packet Appendix
More informationWhat you should know about treating your pain with opioids. Important information on the safe use of opioid pain medicine.
What you should know about treating your pain with opioids Important information on the safe use of opioid pain medicine. If your healthcare provider has determined that opioid therapy is right for you,
More informationReducing Narcotics Misuse and Abuse in Workers Compensation
Reducing Narcotics Misuse and Abuse in Workers Compensation Trusted. Reliable. Sustainable. Page 2 Introduction Narcotics have a long history of being used to therapeutically treat pain resulting from
More informationSAFE PAIN MEDICATION PRESCRIBING GUIDELINES
Prescription drug abuse has been declared an epidemic by the Centers for Disease Control. According to 2012 San Diego Medical Examiner data, the number one cause of non-natural death is due to drug overdoses
More informationUltram (tramadol), Ultram ER (tramadol extended-release tablets); Conzip (tramadol extended-release capsules), Ultracet (tramadol / acetaminophen)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.02.35 Subject: Tramadol Acetaminophen Page: 1 of 8 Last Review Date: September 18, 2015 Tramadol Acetaminophen
More informationThe TIRF REMS Access program is a Food and Drug Administration (FDA) required risk management program
Subject: Important Drug Warning Announcement of a single shared REMS (Risk Evaluation and Mitigation Strategy) program for all Transmucosal Immediate Release Fentanyl (TIRF) products due to the potential
More informationProtecting your employees, the physicians and you. Opioid abuse is being talked about every day. Modern Medical has a solution.
TM Protecting your employees, the physicians and you. Opioid abuse is being talked about every day. Modern Medical has a solution. Goals of Opioid Defense Manager TM Opioids are the most common drugs prescribed
More informationUtah Clinical Guidelines on Prescribing Opioids for Treatment of Pain
Utah Clinical Guidelines on Prescribing Opioids for Treatment of Pain Summary Version Utah Department of Health 009 David N. Sundwall, MD Executive Director Robert T. Rolfs, MD, MPH State Epidemiologist
More informationStrong States, Strong Nation POLICY OPTIONS TO DECREASE RISKS FROM THE USE OF METHADONE AS A PAIN RELIEVER
Strong States, Strong Nation POLICY OPTIONS TO DECREASE RISKS FROM THE USE OF METHADONE AS A PAIN RELIEVER November 17, 2015 Today s Speakers Karmen Hanson, Program Manager, NCSL Cynthia Reilly, Director,
More informationMedical Malpractice Treatment Alprazolam benzodiazepine - A Case Study
Improving Outcomes in Patients Who are Prescribed Alprazolam with Concurrent Use of Opioids Pik-Sai Yung, M.D. Staff Psychiatrist Center for Counseling at Walton Background and Rationale Alprazolam is
More information5317 Cherry Lawn Rd, Huntington, WV 25705 Phone: (304) 302-2078 Fax: (304) 302-0279. Welcome
5317 Cherry Lawn Rd, Huntington, WV 25705 Phone: (304) 302-2078 Fax: (304) 302-0279 Welcome Welcome to Starlight Behavioral Health Opiate Dependence program. At Starlight, we believe that addiction is
More informationSouthlake Psychiatry. Suboxone Contract
Suboxone Contract Thank you for considering Southlake Psychiatry for your Suboxone treatment. Opiate Addiction is a serious condition for which you may find relief with Suboxone treatment. In order to
More informationGenerics First. Opiod Prescription Monitoring
Access, Quality, Cost: Emergency Department Action Plan to Reduce ED Overutilization The Washington Chapter American College of Emergency Physicians (WA-ACEP), with the support of our fellow health care
More informationADVISORY OPINION THE USE OF CONTROLLED SUBSTANCES FOR THE TREATMENT OF CHRONIC PAIN
Janice K. Brewer Governor Arizona State Board of Nursing 4747 North 7 th Street, Suite 200 Phoenix, AZ 85014-3655 Phone (602) 889-5150 Fax - (602) 889-5155 E-Mail: arizona@azbn.gov Home Page: http://www.azbn.gov
More informationHow To Treat Anorexic Addiction With Medication Assisted Treatment
Medication Assisted Treatment for Opioid Addiction Tanya Hiser, MS, LPC Premier Care of Wisconsin, LLC October 21, 2015 How Did We Get Here? Civil War veterans and women 19th Century physicians cautious
More informationUNM Pain Center: Addressing New Mexico s Public Health Crises of Pain, Addiction, and Unintentional Opioid Overdose Deaths
UNM Pain Center: Addressing New Mexico s Public Health Crises of Pain, Addiction, and Unintentional Opioid Overdose Deaths Joanna G Katzman, M.D., M.S.P.H Director, UNM Pain Center Associate Professor,
More informationGuidelines for Use of Controlled Substances for the Treatment of Pain
1.0 Purpose: Use of Controlled Substances for the Treatment of Pain The Physicians Advisory Committee for Controlled Substances of the Medical Society of Delaware supports the Federation of State Medical
More informationARCHIVED BULLETIN. Product No. 2004-L0424-013 SEPTEMBER 2004 U. S. D E P A R T M E N T O F J U S T I C E
BULLETIN INTELLIGENCE Product No. 2004-L0424-013 SEPTEMBER 2004 U. S. D E P A R T M E N T O F J U S T I C E NDIC Within the past 2 years buprenorphine a Schedule III drug has been made available for use
More information18% Role of Pharmacist-Provided Medication Reviews in Workers Compensation Claims Management. Introduction. Role of the Pharmacist
Role of Pharmacist-Provided Medication Reviews in Workers Compensation Claims Management Benjamin Link, PharmD, RPh Introduction According to information from the National Council on Compensation Insurance
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline: CSD - Suboxone Therapeutic Class: Central Nervous System Agents Therapeutic Sub-Class: Analgesics and Antipyretics (Opiate Partial Agonists) Client: County of San
More informationChronic Opioid Use: Comparison of Current Guidelines
Western Occupational and Environmental Medical Association Chronic Opioid Use: Comparison of Current Guidelines INTRODUCTION Recent controversies about opioid misuse, including misuse among patients with
More informationMethadone for Substance Abuse. By: Angela M. Martinez
Methadone for Substance Abuse By: Angela M. Martinez When taken orally once a day, methadone suppresses narcotic withdrawal for between 24 and 36 hours. Because methadone is effective in eliminating withdrawal
More informationBlueprint for Prescriber Continuing Education Program
CDER Final 10/25/11 Blueprint for Prescriber Continuing Education Program I. Introduction: Why Prescriber Education is Important Health care professionals who prescribe extended-release (ER) and long-acting
More informationGuidelines for the Use of Controlled Substances in the Treatment of Pain Adopted by the New Hampshire Medical Society, July 1998
Guidelines for the Use of Controlled Substances in the Treatment of Pain Adopted by the New Hampshire Medical Society, July 1998 Section I: Preamble The New Hampshire Medical Society believes that principles
More informationPATIENT TREATMENT AGREEMENT
PATIENT TREATMENT AGREEMENT Patient Name: : As a participant in buprenorphine treatment for opioid misuse and dependence, I freely and voluntarily agree to accept this treatment agreement as follows: I
More informationFor a Healthier America: Reducing Prescription Drug Misuse and Abuse
For a Healthier America: Reducing Prescription Drug Misuse and Abuse The misuse and abuse of prescription medicines is a growing public health problem. In addition to the tragic toll on families and communities,
More informationPrescription drug abuse trends. Minnesota s Prescription Monitoring Program. Minnesota Rural Health Conference June 25, 2013 Duluth
Prescription drug abuse trends Minnesota s Prescription Monitoring Program Carol Falkowski Drug Abuse Dialogues www.drugabusedialogues.com Barbara Carter, Manager MN Board of Pharmacy www.pmp.pharmacy.state.mn.us
More informationDo You Know Where the Drugs Are Going? Partners in Integrity
Do You Know Where the Drugs Are Going? Partners in Integrity Objectives At the conclusion of this presentation, participants will be able to: Identify common types of drug diversion activities. List at
More informationDrug Testing to Support Pain Management
NATIONAL REFERENCE LABORATORY Drug Testing to Support Pain Management 500 Chipeta Way, Salt Lake City, UT 84108 (800) 522-2787 (801) 583-2787 www.aruplab.com www.arupconsult.com ARUP is an enterprise of
More informationDo You Know Where the Drugs Are Going?
Do You Know Where the Drugs Are Going? Presentation Objectives At the conclusion of this presentation, participants will be able to: Identify common types of drug diversion activities. List at least four
More informationOpioid overdose can occur when a patient misunderstands the directions
Facts About Opioid Overdose How Does an Overdose Occur? Opioid overdose can occur when a patient misunderstands the directions for use, accidentally takes an extra dose, or deliberately misuses a prescription
More informationCDC s Prevention Efforts to Address Prescription Opioid Epidemic
CDC s Prevention Efforts to Address Prescription Opioid Epidemic Jan Losby, PhD, MSW Lead, Prescription Drug Overdose Health Systems and State Support Team Division of Unintentional Injury Prevention NASBO
More informationMichigan Guidelines for the Use of Controlled Substances for the Treatment of Pain
Michigan Guidelines for the Use of Controlled Substances for the Treatment of Pain Section I: Preamble The Michigan Boards of Medicine and Osteopathic Medicine & Surgery recognize that principles of quality
More informationOpioid Treatment Agreement
Opioid Treatment Agreement 1. I understand that my provider and I will work together to find the most appropriate treatment for my chronic pain. I understand the goals of treatment are not to eliminate
More informationNaltrexone Pellet Treatment for Opiate, Heroin, and Alcohol Addiction. Frequently Asked Questions
Naltrexone Pellet Treatment for Opiate, Heroin, and Alcohol Addiction Frequently Asked Questions What is Naltrexone? Naltrexone is a prescription drug that effectively blocks the effects of heroin, alcohol,
More informationDEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Medicare & Medicaid Services. NEW products from the Medicare Learning Network (MLN)
Medicare Advantage Outreach and Education Bulletin Anthem Blue Cross Prescription Drug Monitoring Programs Prescription drug abuse and diversion are acute problems in the area of pain management. The Centers
More informationNurse Practitioner Controlled Substances Post Survey Analysis. May, 2013
Nurse Practitioner Controlled Substances Post Survey Analysis May, 2013 Contents Table of Figures... 1 Executive Summary... 2 Nurse Practitioner Controlled Substances Post Survey Analysis... 3 Background...
More informationMARYLAND EMERGENCY DEPARTMENT OPIOID PRESCRIBING GUIDELINES
MARYLAND EMERGENCY DEPARTMENT OPIOID PRESCRIBING GUIDELINES 1. Hospitals, in conjunction with Emergency Department personnel, should develop a process to screen for substance misuse that includes services
More informationST. CLAIR COUNTY COMMUNITY MENTAL HEALTH Date Issued: 07/09 Date Revised: 09/11;03/13;06/14;07/15
ST. CLAIR COUNTY COMMUNITY MENTAL HEALTH Date Issued: 07/09 Date Revised: 09/11;/13;06/14;07/15 WRITTEN BY Jim Johnson Page 1 REVISED BY AUTHORIZED BY Jessica Moeller Debra Johnson I. APPLICATION: THUMB
More informationTestimony Engrossed House Bill 1101 Department of Human Services Senate Human Services Committee Senator Judy Lee, Chairman February 19, 2013
Testimony Engrossed House Bill 1101 Department of Human Services Senate Human Services Committee Senator Judy Lee, Chairman February 19, 2013 Chairman Lee, members of the Senate Human Services Committee,
More informationTauto-Mod. Homeopathy for Addictions
Homeopathy for Addictions Tauto-Mod Methods and outcomes of the Tauto-Mod prescribing system and an analysis of the addictions homeopathic medication pilot project in 2012. Based on a newly developed prescribing
More informationPrescribers required to check PDMP before first prescription for Controled Substances for new patient.
State, District, or Territory Alabama Arizona Arkansas Colorado Connecticut Delaware Georgia Guam Criteria for Mandatory Enrollment or Query of PDMP Before renewing an Alabama Controlled Substances Certificate,
More informationGetting the best result from Opioid medicine. in the management of chronic pain
Getting the best result from Opioid medicine in the management of chronic pain Your doctor has prescribed you opioid medicine to help you manage your chronic pain. This patient information leaflet gives
More informationA Healthesystems Clinical Analysis. Insidious Incrementalism of Opioid Use in Workers Compensation
A Healthesystems Clinical Analysis Insidious Incrementalism of Opioid Use in Workers Compensation Prescription opioid use in the United States has grown significantly over the past 20 years. In 1991, there
More informationSubstance Use: Addressing Addiction and Emerging Issues
MODULE 6: SUBSTANCE USE: ADDRESSING ADDICTION AND EMERGING ISSUES Substance Use: Addressing Addiction and Emerging Issues Martha C. Romney, RN, MS, JD, MPH Assistant Professor Jefferson School of Population
More informationBackground & Significance
The Impact Of A Structured Opioid Renewal Clinic On Aberrant Drug Behavior Outcomes At A Northeastern VA Medical Center Salimah H. Meghani, PhD, MBE, CRNP Assistant Professor, University of Pennsylvania
More informationMEETING OF THE DRUG SAFETY AND RISK MANAGEMENT ADVISORY COMMITTEE MEETING: RISKS AND BENEFITS OF HYDROCODONE COMBINATION ANALGESIC PRODUCTS
MEETING OF THE DRUG SAFETY AND RISK MANAGEMENT ADVISORY COMMITTEE MEETING: RISKS AND BENEFITS OF HYDROCODONE COMBINATION ANALGESIC PRODUCTS David Gaugh, R.Ph. Senior Vice President for Sciences and Regulatory
More informationEXPLORING NALOXONE UPTAKE AND USE PUBLIC MEETING July 01 02, 2015 Fred Wells Brason II fbrason@projectlazarus.org
EXPLORING NALOXONE UPTAKE AND USE PUBLIC MEETING July 01 02, 2015 Fred Wells Brason II fbrason@projectlazarus.org Disclosures Project Lazarus Zogenix Charitable Contribution 2015 Kaléo Charitable Contribution
More informationSUPPORTING WOMEN USING OPIATES IN PREGNANCY: A Guideline for Primary Care Providers May, 2011
INTRODUCTION SUPPORTING WOMEN USING OPIATES IN PREGNANCY: A Guideline for Primary Care Providers May, 2011 Prevalence of Opiate Use and Impact on Maternal, Fetal, and Neonatal Health: The prevalence of
More informationMQAC Rules for the Management of Chronic Non-Cancer Pain
MQAC Rules for the Management of Chronic Non-Cancer Pain Effective January 2, 2012 246-919-850 Pain management Intent. These rules govern the use of opioids in the treatment of patients for chronic noncancer
More informationPain Management Regulations Affect More Than Pain Management Specialists January 2012. Of counsel to
Pain Management Regulations Affect More Than Pain Management Specialists January 2012 LINDA A. KEEN MSN, JD, LHCRM LAW OFFICE OF LINDA A. KEEN P.A. TALLAHASSEE, FL Of counsel to Pain Management Regulations
More informationTreatment of Prescription Opioid Dependence
Treatment of Prescription Opioid Dependence Roger D. Weiss, MD Chief, Division of Alcohol and Drug Abuse McLean Hospital, Belmont, MA Professor of Psychiatry, Harvard Medical School, Boston, MA Prescription
More informationMSD Guidelines for the Use of Controlled Substances for the Treatment of Pain
GUIDELINES MSD Guidelines for the Use of Controlled Substances for the Treatment of Pain To address the current epidemic of prescription drug abuse, your Medical Society has been working closely with the
More informationMethadone Maintenance Treatment for Opioid Dependence
COLLEGE OF PHYSICIANS AND SURGEONS OF ONTARIO P O L I C Y S TAT E M E N T # 2 1 0 Methadone Maintenance Treatment for Opioid Dependence APPROVED BY COUNCIL: PUBLICATION DATE: KEY WORDS: REFERENCE MATERIALS:
More informationHow To Get A Tirf
Transmucosal Immediate Release Fentanyl (TIRF) Products Risk Evaluation and Mitigation Strategy (REMS) Education Program for Prescribers and Pharmacists Products Covered Under This Program Abstral (fentanyl)
More informationCare Management Council submission date: August 2013. Contact Information
Clinical Practice Approval Form Clinical Practice Title: Acute use of Buprenorphine for the Treatment of Opioid Dependence and Detoxification Type of Review: New Clinical Practice Revisions of Existing
More informationA Review of the Impacts of Opiate Use in Ontario: Summary Report
A Review of the Impacts of Opiate Use in Ontario: Summary Report A Provincial Summary Report of the Impacts of the Discontinuation of Oxycontin in Ontario: January to August 2013 December 2013 This report
More informationWHAT WE KNOW. Collective Action Issue Brief #2 Updated June 2014 PRESCRIPTION PAIN MEDICATION MISUSE
Collective Action Issue Brief #2 Updated June 2014 PRESCRIPTION PAIN MEDICATION MISUSE WHAT WE KNOW The misuse and abuse of prescription drugs has become a leading cause of harm among New Hampshire adults,
More informationMedical marijuana for pain and anxiety: A primer for methadone physicians. Meldon Kahan MD CPSO Methadone Prescribers Conference November 6, 2015
Medical marijuana for pain and anxiety: A primer for methadone physicians Meldon Kahan MD CPSO Methadone Prescribers Conference November 6, 2015 Conflict of interest statement No conflict of interest to
More informationInformation for Pharmacists
Page 43 by 42 CFR part 2. A general authorization for the release of medical or other information is NOT sufficient for this purpose. Information for Pharmacists SUBOXONE (buprenorphine HCl/naloxone HCl
More informationDisclosure. C.R. Sullivan, MD 1. Carl R. Sullivan, M.D. Professor and Director Addictions Program csullivan@hsc.wvu.edu. The West Virginia Model
West Virginia University School of Medicine BEHAVIORAL MEDICINE & PSYCHIATRY Morgantown, WV Carl R. Sullivan, M.D. Professor and Director Addictions Program csullivan@hsc.wvu.edu Disclosure Reckitt Benckiser
More information